The history of clinical trials in ALS/MND has been fraught with failures. It has not been uncommon for a potential therapy to show promise in Phase 2 trial results, then prove to be ineffective in the subsequent, larger-scale Phase 3 trial. Clinical trials take a considerable amount of time, resources, and funding, and as such there have been numerous efforts in the field of ALS/MND to optimize clinical trials to improve their efficiency and effectiveness. From outcome measures to entry criteria, this webinar will explore the lessons we have learned from the failed trials of the past, and how those have been integrated in to our optimization of clinical trials of the future.